You are here

Article Text

Article menu
Download PDFPDF
ABN Abstracts 2022
Poster presentations
151 Updated analysis of pregnancy outcomes for patients with MS in a dimethyl fumarate exposure registry
  1. David Rog1,
  2. Kerstin Hellwig2,
  3. Christopher McGuigan3,
  4. Oksana Mokliatchouk4,
  5. Filipe Branco4,
  6. Jennifer Lyons4,
  7. Nicholas Everage4
  1. 1Manchester Centre for Clinical Neurosciences, Salford Royal
  2. 2University of Bochum, Neurological Clinic, Bochum, Germany
  3. 3St. Vincent’s University Hospital, Dublin, Ireland
  4. 4Biogen, USA

Abstract

Introduction Dimethyl fumarate (DMF) is not recommended during pregnancy and should only be used if the potential benefit justifies potential foetal risk. Given limited pregnancy data, the UK and Ireland have enrolled DMF-exposed pregnant women in an ongoing international registry assessing pregnancy outcomes. In the general population, 62% of pregnancies end in live birth, 22% in abortion, and 16% in foetal loss, with similar rates in multiple sclerosis (MS) patients.

Methods Women with MS exposed to DMF since the first day of their last menstrual period before con- ception/during pregnancy were included. UK/Ireland Coordinating Centres liaised directly with patients and healthcare providers.

Results As of March 2021, 403 patients (19 UK/Ireland) were enrolled. Of 350 reported pregnancy outcomes (19 UK/Ireland), 329 (94%) represented live births (100% UK/Ireland). Of 326 infants with known gestational age,

298 births (91%) were full-term (100% UK/Ireland) and 28 (9%) premature (<37 weeks). Of the 21 (6%) cases of foetal loss, 19 were spontaneous abortions (1 each ectopic and molar pregnancy) and 2 foetal deaths (>28 weeks). There was one neonatal death. Nine infants (2 UK/Ireland) had EUROCAT-confirmed birth defects.

Conclusions The observations are consistent with MS and general populations.

Support Biogen. Disclosures on poster.

https://doi.org/10.1136/jnnp-2022-abn2.195

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.